Phase 1 Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with multiple myeloma, confirmed through a laboratory test of tissue or cell samples, using recognised international diagnostic standards
- People who have at least one area of myeloma activity detected on a specialised imaging scan (PET/CT or PET/MRI), where the affected area shows higher activity than the liver on the scan
- People aged 18 years or older
- People whose liver function blood test results (bilirubin, AST, and ALT) are within acceptable ranges as determined by the trial laboratory
- People whose kidneys are functioning at or above a minimum level, based on a standard calculation or blood test result
- People who are able to understand and are willing to sign a written consent form
Who may not be able to join:
- People who have any health condition that, in the lead investigator's judgement, could affect their ability to follow the study procedures or raise safety concerns
- People who are currently pregnant or breastfeeding/chestfeeding
- People who are able to become pregnant and do not have a negative pregnancy test (urine or blood) within 72 hours before receiving the study imaging agent — if the urine test result is unclear or positive, a blood test is required, and a positive blood test result would mean the person cannot join
- People who are able to become pregnant are considered in this category unless records confirm they have not had a menstrual period for 12 or more consecutive months (with no other medical explanation), or they have had a surgical procedure to remove the uterus and/or both ovaries
- People who are pregnant or breastfeeding/chestfeeding are excluded because the study imaging agent may carry unknown risks to an unborn baby or nursing child
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Robert Flavell, MD, PhD, University of California, San Francisco
Phone: (415) 514-8987
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Sensitivity of metastatic lesion; Median maximum standardized uptake value (SUVmax); Median Standardized Uptake Value averaged across lesions (SUVmax-avg)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.